308 related articles for article (PubMed ID: 31876399)
1. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
Yarchoan M; Huang CY; Zhu Q; Ferguson AK; Durham JN; Anders RA; Thompson ED; Rozich NS; Thomas DL; Nauroth JM; Rodriguez C; Osipov A; De Jesus-Acosta A; Le DT; Murphy AG; Laheru D; Donehower RC; Jaffee EM; Zheng L; Azad NS
Cancer Med; 2020 Feb; 9(4):1485-1494. PubMed ID: 31876399
[TBL] [Abstract][Full Text] [Related]
2. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.
Segal NH; Cercek A; Ku G; Wu AJ; Rimner A; Khalil DN; Reidy-Lagunes D; Cuaron J; Yang TJ; Weiser MR; Romesser PB; Stadler ZK; Varghese AM; Ganesh K; Yaeger R; Connell LC; Faleck D; Abou-Alfa GK; Mcauliffe KC; Vaiskauskas P; Solter ML; Ogle M; Adamow MJ; Holland A; Vedantam P; Wong P; Merghoub T; Vakiani E; Hollmann TJ; Juluru K; Chou JF; Capanu M; Erinjeri J; Solomon S; Yamada Y; Kemeny N; Crane CH; Saltz LB
Clin Cancer Res; 2021 Apr; 27(8):2200-2208. PubMed ID: 33504552
[TBL] [Abstract][Full Text] [Related]
3. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.
Kuang C; Park Y; Augustin RC; Lin Y; Hartman DJ; Seigh L; Pai RK; Sun W; Bahary N; Ohr J; Rhee JC; Marks SM; Beasley HS; Shuai Y; Herman JG; Zarour HM; Chu E; Lee JJ; Krishnamurthy A
Clin Epigenetics; 2022 Jan; 14(1):3. PubMed ID: 34991708
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
Tsujikawa T; Crocenzi T; Durham JN; Sugar EA; Wu AA; Onners B; Nauroth JM; Anders RA; Fertig EJ; Laheru DA; Reiss K; Vonderheide RH; Ko AH; Tempero MA; Fisher GA; Considine M; Danilova L; Brockstedt DG; Coussens LM; Jaffee EM; Le DT
Clin Cancer Res; 2020 Jul; 26(14):3578-3588. PubMed ID: 32273276
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
Haag GM; Springfeld C; Grün B; Apostolidis L; Zschäbitz S; Dietrich M; Berger AK; Weber TF; Zoernig I; Schaaf M; Waberer L; Müller DW; Al-Batran SE; Halama N; Jaeger D
Eur J Cancer; 2022 May; 167():112-122. PubMed ID: 35427833
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.
Le Cesne A; Marec-Berard P; Blay JY; Gaspar N; Bertucci F; Penel N; Bompas E; Cousin S; Toulmonde M; Bessede A; Fridman WH; Sautes-Fridman C; Kind M; Le Loarer F; Pulido M; Italiano A
Eur J Cancer; 2019 Sep; 119():151-157. PubMed ID: 31442817
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
Cousin S; Cantarel C; Guegan JP; Gomez-Roca C; Metges JP; Adenis A; Pernot S; Bellera C; Kind M; Auzanneau C; Le Loarer F; Soubeyran I; Bessede A; Italiano A
Clin Cancer Res; 2021 Apr; 27(8):2139-2147. PubMed ID: 33495314
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
Overman M; Javle M; Davis RE; Vats P; Kumar-Sinha C; Xiao L; Mettu NB; Parra ER; Benson AB; Lopez CD; Munugalavadla V; Patel P; Tao L; Neelapu S; Maitra A
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114502
[TBL] [Abstract][Full Text] [Related]
10. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
Cartwright E; Slater S; Saffery C; Tran A; Turkes F; Smith G; Aresu M; Kohoutova D; Terlizzo M; Zhitkov O; Rana I; Johnston EW; Sanna I; Smyth E; Mansoor W; Fribbens C; Rao S; Chau I; Starling N; Cunningham D
ESMO Open; 2024 Apr; 9(4):102971. PubMed ID: 38518549
[TBL] [Abstract][Full Text] [Related]
12. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
Kim DW; Tan E; Zhou JM; Schell MJ; Martinez M; Yu J; Carballido E; Mehta R; Strosberg J; Imanirad I; Kim RD
Br J Cancer; 2021 May; 124(11):1803-1808. PubMed ID: 33828254
[TBL] [Abstract][Full Text] [Related]
13. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.
Emens LA; Asquith JM; Leatherman JM; Kobrin BJ; Petrik S; Laiko M; Levi J; Daphtary MM; Biedrzycki B; Wolff AC; Stearns V; Disis ML; Ye X; Piantadosi S; Fetting JH; Davidson NE; Jaffee EM
J Clin Oncol; 2009 Dec; 27(35):5911-8. PubMed ID: 19805669
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
Gubens MA; Sequist LV; Stevenson JP; Powell SF; Villaruz LC; Gadgeel SM; Langer CJ; Patnaik A; Borghaei H; Jalal SI; Fiore J; Saraf S; Raftopoulos H; Gandhi L
Lung Cancer; 2019 Apr; 130():59-66. PubMed ID: 30885353
[TBL] [Abstract][Full Text] [Related]
15. A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint.
Bever KM; Thomas DL; Zhang J; Diaz Rivera EA; Rosner GL; Zhu Q; Nauroth JM; Christmas B; Thompson ED; Anders RA; Judkins C; Liu M; Jaffee EM; Ahuja N; Zheng L; Azad NS
Clin Epigenetics; 2021 Feb; 13(1):25. PubMed ID: 33531075
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
Wu AA; Bever KM; Ho WJ; Fertig EJ; Niu N; Zheng L; Parkinson RM; Durham JN; Onners B; Ferguson AK; Wilt C; Ko AH; Wang-Gillam A; Laheru DA; Anders RA; Thompson ED; Sugar EA; Jaffee EM; Le DT
Clin Cancer Res; 2020 Oct; 26(19):5129-5139. PubMed ID: 32591464
[TBL] [Abstract][Full Text] [Related]
17. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
Anders CK; Woodcock MG; Van Swearingen AED; Moore DT; Sambade MJ; Laurie S; Robeson A; Kolupaev O; Cuaboy LA; Garrett AL; McKinnon K; Cowens K; Bortone D; Calhoun BC; Wilkinson AD; Carey L; Jolly T; Muss H; Reeder-Hayes K; Kaltman R; Jankowitz R; Gudena V; Olajide O; Perou C; Dees EC; Vincent BG; Serody JS
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35121644
[TBL] [Abstract][Full Text] [Related]
19. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
Thomas J; Leal A; Overman MJ
Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
